|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
North Suffolk Mental Health Association |
|---|---|
| Information provided by: | North Suffolk Mental Health Association |
| ClinicalTrials.gov Identifier: | NCT00320697 |
Purpose
This study seeks to determine if continued treatment with bupropion and nicotine replacement therapy (NRT) can reduce the smoking relapse rate in patients with schizophrenia.
| Condition | Intervention | Phase |
|---|---|---|
|
Schizophrenia Schizoaffective Disorder Smokers |
Drug: bupropion Drug: transdermal nicotine patch Drug: short-acting nicotine replacement therapy |
Phase IV |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study |
| Official Title: | A Trial of the Effects of Bupropion, Nicotine Replacement Therapy and CBT on Smoking Cessation and Smoking Relapse in Patients With Schizophrenia |
| Estimated Enrollment: | 300 |
| Study Start Date: | April 2006 |
Show Detailed Description
Eligibility| Ages Eligible for Study: | 18 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria
Diagnosis of dementia, neurodegenerative disease, seizure disorder, current anorexia/bulimia nervosa, current substance abuse or dependence disorders, including alcohol, active within the last 3 months or any Axis I DSM-IV diagnosis other than schizophrenia or schizoaffective disorder.
(*Note: Subjects with a seizure disorder who would not be medically eligible for bupropion may be allowed to participate, but will not be prescribed bupropion or randomized; rather, they will continue to receive open treatment through the relapse prevention phase.)
Contacts and Locations| United States, Massachusetts | |
| Freedom Trail Clinic | |
| Boston, Massachusetts, United States, 02114 | |
| Principal Investigator: | A Eden Evins, MD, MPH | North Suffolk Mental Health Association |
More Information
| Responsible Party: | Massachusetts General Hospital ( A Eden Evins, MD, MPH ) |
| Study ID Numbers: | CORRC 15-2005, HRC#2005-p-001950 |
| Study First Received: | April 28, 2006 |
| Last Updated: | May 15, 2009 |
| ClinicalTrials.gov Identifier: | NCT00320697 History of Changes |
| Health Authority: | United States: Institutional Review Board |
|
schizophrenia smoking cessation relapse prevention nicotine |
bupropion cognitive behavioral therapy nicotine replacement therapy |
|
Dopamine Uptake Inhibitors Nicotine polacrilex Neurotransmitter Agents Nicotinic Agonists Psychotropic Drugs Central Nervous System Stimulants Cholinergic Agents Schizophrenia Smoking Dopamine |
Mental Disorders Nicotine Bupropion Dopamine Agents Psychotic Disorders Peripheral Nervous System Agents Antidepressive Agents, Second-Generation Antidepressive Agents Schizophrenia and Disorders with Psychotic Features |
|
Dopamine Uptake Inhibitors Nicotine polacrilex Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Cholinergic Agonists Molecular Mechanisms of Pharmacological Action Nicotinic Agonists Physiological Effects of Drugs Psychotropic Drugs Cholinergic Agents Schizophrenia Habits Smoking Nicotine |
Mental Disorders Therapeutic Uses Ganglionic Stimulants Psychotic Disorders Antidepressive Agents, Second-Generation Schizophrenia and Disorders with Psychotic Features Antidepressive Agents Central Nervous System Stimulants Pharmacologic Actions Autonomic Agents Bupropion Dopamine Agents Peripheral Nervous System Agents Central Nervous System Agents |